Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

10.78
+0.87008.78%
Post-market: 12.001.22+11.31%18:57 EDT
Volume:4.36M
Turnover:47.55M
Market Cap:1.22B
PE:-3.20
High:11.14
Open:10.30
Low:10.27
Close:9.91
Loading ...

Dyne Therapeutics Inc - Expects Completion of Enrollment for Registrational Expansion Cohort in Mid-2025

THOMSON REUTERS
·
10 Jan

Jefferies healthcare analyst holds an analyst/industry conference call

TIPRANKS
·
19 Dec 2024

Baird Initiates Dyne Therapeutics at Outperform With $46 Price Target

MT Newswires Live
·
13 Dec 2024

Dyne Therapeutics Initiated at Outperform by Baird

Dow Jones
·
13 Dec 2024

Dyne Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Target Price $46

THOMSON REUTERS
·
13 Dec 2024

Dyne, Avidity initiated at outperform by RBC on DM1 drugs

seekingalpha
·
27 Nov 2024

RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target

MT Newswires Live
·
26 Nov 2024

U.S. RESEARCH ROUNDUP-Allstate, Mongodb, Primerica

Reuters
·
26 Nov 2024

Dyne Therapeutics initiated with an Outperform at RBC Capital

TIPRANKS
·
26 Nov 2024

Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey
·
22 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

Dyne Therapeutics Reveals Q3 Results and Trial Updates

TIPRANKS
·
14 Nov 2024

Dyne Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
14 Nov 2024

Dyne Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Dyne Therapeutics' Q3 Loss Narrows

MT Newswires Live
·
12 Nov 2024

Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026

Benzinga
·
12 Nov 2024

Dyne Therapeutics reports Q3 EPS (96c), consensus (71c)

TIPRANKS
·
12 Nov 2024